203 related articles for article (PubMed ID: 26740252)
1. The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression.
Ho N; Morrison J; Silva A; Coomber BL
Biosci Rep; 2016 Jan; 36(1):e00299. PubMed ID: 26740252
[TBL] [Abstract][Full Text] [Related]
2. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate.
Chen Z; Zhang H; Lu W; Huang P
Biochim Biophys Acta; 2009 May; 1787(5):553-60. PubMed ID: 19285479
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.
Nakano A; Miki H; Nakamura S; Harada T; Oda A; Amou H; Fujii S; Kagawa K; Takeuchi K; Ozaki S; Matsumoto T; Abe M
J Bioenerg Biomembr; 2012 Feb; 44(1):31-8. PubMed ID: 22298254
[TBL] [Abstract][Full Text] [Related]
4. 3-Bromopyruvate treatment induces alterations of metabolic and stress-related pathways in glioblastoma cells.
Chiasserini D; Davidescu M; Orvietani PL; Susta F; Macchioni L; Petricciuolo M; Castigli E; Roberti R; Binaglia L; Corazzi L
J Proteomics; 2017 Jan; 152():329-338. PubMed ID: 27890797
[TBL] [Abstract][Full Text] [Related]
5. 3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau.
Ko YH; Niedźwiecka K; Casal M; Pedersen PL; Ułaszewski S
Yeast; 2019 Apr; 36(4):211-221. PubMed ID: 30462852
[TBL] [Abstract][Full Text] [Related]
6. MCT1, MCT4 and CD147 expression and 3-bromopyruvate toxicity in colorectal cancer cells are modulated by the extracellular conditions.
Pereira-Vieira J; Azevedo-Silva J; Preto A; Casal M; Queirós O
Biol Chem; 2019 May; 400(6):787-799. PubMed ID: 30699066
[TBL] [Abstract][Full Text] [Related]
7. Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro.
Wang K; Fan H; Chen Q; Ma G; Zhu M; Zhang X; Zhang Y; Yu J
Anticancer Drugs; 2015 Jan; 26(1):15-24. PubMed ID: 25229889
[TBL] [Abstract][Full Text] [Related]
8. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue.
Pedersen PL
J Bioenerg Biomembr; 2012 Feb; 44(1):1-6. PubMed ID: 22382780
[TBL] [Abstract][Full Text] [Related]
9. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer.
Han CY; Patten DA; Lee SG; Parks RJ; Chan DW; Harper ME; Tsang BK
Mol Carcinog; 2019 Nov; 58(11):2161-2174. PubMed ID: 31486135
[TBL] [Abstract][Full Text] [Related]
10. Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin.
Rai Y; Yadav P; Kumari N; Kalra N; Bhatt AN
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31506393
[TBL] [Abstract][Full Text] [Related]
11. Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells.
Gao X; Han H
J Cell Biochem; 2018 Jun; 119(6):4967-4974. PubMed ID: 29384225
[TBL] [Abstract][Full Text] [Related]
12. Metabolic reprogramming and AMPKα1 pathway activation by caulerpin in colorectal cancer cells.
Yu H; Zhang H; Dong M; Wu Z; Shen Z; Xie Y; Kong Z; Dai X; Xu B
Int J Oncol; 2017 Jan; 50(1):161-172. PubMed ID: 27922662
[TBL] [Abstract][Full Text] [Related]
13. 3-Bromopyruvate enhances TRAIL-induced apoptosis in human nasopharyngeal carcinoma cells through CHOP-dependent upregulation of TRAIL-R2.
Can Z; Lele S; Zhirui Z; Qiong P; Yuzhong C; Lingling L; Surong Z; Yiming S; Pei Z; Chenchen J; Liu H
Anticancer Drugs; 2017 Aug; 28(7):739-749. PubMed ID: 28471808
[TBL] [Abstract][Full Text] [Related]
14. Genetically programmable cell membrane-camouflaged nanoparticles for targeted combination therapy of colorectal cancer.
Yang Y; Liu Q; Wang M; Li L; Yu Y; Pan M; Hu D; Chu B; Qu Y; Qian Z
Signal Transduct Target Ther; 2024 Jun; 9(1):158. PubMed ID: 38862461
[TBL] [Abstract][Full Text] [Related]
15. Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.
El Sayed SM; Mohamed WG; Seddik MA; Ahmed AS; Mahmoud AG; Amer WH; Helmy Nabo MM; Hamed AR; Ahmed NS; Abd-Allah AA
Chin J Cancer; 2014 Jul; 33(7):356-64. PubMed ID: 24636230
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer.
Sun Y; Liu Z; Zou X; Lan Y; Sun X; Wang X; Zhao S; Jiang C; Liu H
J Bioenerg Biomembr; 2015 Aug; 47(4):319-29. PubMed ID: 26054380
[TBL] [Abstract][Full Text] [Related]
17. Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics.
Bhardwaj V; Rizvi N; Lai MB; Lai JC; Bhushan A
Anticancer Res; 2010 Mar; 30(3):743-9. PubMed ID: 20392992
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester.
Tang Z; Yuan S; Hu Y; Zhang H; Wu W; Zeng Z; Yang J; Yun J; Xu R; Huang P
J Bioenerg Biomembr; 2012 Feb; 44(1):117-25. PubMed ID: 22350014
[TBL] [Abstract][Full Text] [Related]
19. Characterization of acetate transport in colorectal cancer cells and potential therapeutic implications.
Ferro S; Azevedo-Silva J; Casal M; Côrte-Real M; Baltazar F; Preto A
Oncotarget; 2016 Oct; 7(43):70639-70653. PubMed ID: 28874966
[TBL] [Abstract][Full Text] [Related]
20. TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells.
Straus DS
Mol Cancer; 2013 Jul; 12():78. PubMed ID: 23866118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
